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Backgrounds: Recent studies have identified the role of serologic markers in characterizing disease phenotype, location, complications, and sever-
ity among Northern Europeans (NE) with Crohn’s disease (CD). However, very little is known about the role of serology in CD among African 
Americans (AA). Our study explored the relationship between serology and disease phenotype in AA with CD, while controlling for genetic ancestry.
Methods: AAs with CD were enrolled as participants through multicenter collaborative efforts. Serological levels of IgA anti-Saccharomyces 
cervisiae antibody (ASCA), IgG ASCA, E. coli outermembrane porin C, anti-CBir1, and ANCA were measured using enzyme-linked immuno-
sorbent assays. Genotyping was performed using Illumina immunochip technology; an admixture rate was calculated for each subject. Multiple 
imputation by chained equations was performed to account for data missing at random. Logistic regression was used to calculate adjusted odds 
ratio (OR) for associations between serological markers and both complicated disease and disease requiring surgery.
Results: A total of 358 patients were included in the analysis. The majority of our patients had inflammatory, noncomplicated disease (58.4%), perianal 
disease (55.7%), and documented colonic inflammation (86.8%). On multivariable analysis, both IgG ASCA and OmpC were associated with compli-
cated disease (OR, 2.67; 95% CI, 1.67–4.28; OR, 2.23; 95% CI, 1.41–3.53, respectively) and disease requiring surgery (OR, 2.51; 95% CI, 1.49–4.22; OR, 
3.57; 95% CI, 2.12–6.00). NE admixture to the African genome did not have any associations or interactions in relation to clinical outcome.
Conclusions: Our study comprises the largest cohort of AAs with CD. The utility of serological markers for the prognosis of CD in NE applies 
equally to AA populations.
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Crohn’s disease (CD) encompasses a spectrum of chronic, relapsing, and remitting inflammatory symptoms that 
affect pediatric and adult populations, with the peak incidence 
occurring in adolescents and young adults. Recent studies 
have explored the relationship between genetic, microbial, 
and immune responses in CD, including the role of antimicro-
bial serologies in characterizing disease phenotype, clinical 
course, and natural history.1–4 In particular, significant asso-
ciations have been identified between the presence of anti-
bodies to Saccharomyces cerevisiae (ASCA IgA and ASCA 
IgG), antibodies to Escherichia coli outer membrane porin C 
(anti-OmpC), antibodies to CBIR1 flagellin (anti-CBir1) and 
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perinuclear anti-nuclear cytoplasmic antibodies (pANCA) with 
disease phenotype and clinical outcomes.5 ASCA, anti-CBir1, 
and anti-OmpC positivities have been associated with ileal dis-
ease, stricturing, and/or penetrating disease, a higher risk for 
surgery, and earlier disease onset, while ANCA positivity has 
been associated with colonic disease and a more “benign” dis-
ease course.4 The vast majority of these studies have originated 
from North America and Europe and have primarily focused 
on patient populations of Caucasians of Western European 
decent. Although the findings of these studies have contributed 
to our understanding of CD pathogenesis as well as to the devel-
opment of tools both for differentiating types of inflammatory 
bowel disease (IBD) and predicting risk stratification, t hese 
findings need to be explored in non-Caucasian populations.1 
An understanding of the relevance of these markers in demo-
graphically diverse groups is necessary if the potential clinical 
utility of IBD serology is to be extended to all populations.
Historically considered a disease of  Northern European 
(NE) ancestries, it is now recognized that CD affects every 
race and ethnicity, with a rising incidence in non-European 
populations. Furthermore, CD characteristics, treatment 
responses, and disease course can vary in different popula-
tions.6–8 Specifically, t he e pidemiology, g enetics, a nd n atural 
history of  IBD among African Americans (AAs) remains 
severely understudied.6–8 With regards to IBD-associated 
serology in AA, there has only been 1 study to date, which 
identified that ASCA has a similar sensitivity but lower spe-
cificity for C D, a s w ell a s a n a ssociation w ith i leal i nvolve-
ment, complicated behavior, and surgery in AAs with CD.9 
In addition to limiting investigations on ASCA alone, this 
study was further limited by its reliance on self-reported eth-
nicity. AAs are an admixed population, and the AA genome 
on average is comprised of  80% West African ancestry and 
20% European ancestry.10 Due to differences in environmental 
and genetic influences a mong v arious e thnic p opulations, 
there is a need to further delineate the diagnostic value of 
these biomarkers among AA.4 Although genetic susceptibility 
among Caucasians and AAs is mostly similar, differences 
exist, including the association with NOD2 mutations, which 
is less influential in AAs, possibly due to Caucasian admixture 
among AAs. Hence, exploration of  these serological markers 
in AAs among CD phenotypes may allow clinicians to risk 
stratify in an important and growing demographic of  IBD 
patients. Our study was designed to explore the relationship 
between antibodies and disease phenotype in AAs with CD 
while controlling for genetic ancestry.
MATERIALS AND METHODS
Study Design and Hypothesis
We conducted a cross-sectional study testing the 
hypoth-esis that serological levels of IgA ASCA, IgG 
ASCA, anti-OmpC, anti-CBir1, and ANCA are a risk factor 
for complicated 
disease and disease requiring surgery among AAs with CD. 
The Institutional Review Board of the participating sites 
(Emory University, Children’s Hospital of Atlanta, Atlanta VA 
Medical Center Children’s Hospital of Philadelphia, Cincinnati 
Children’s Hospital Medical Center, University Hospitals Case 
Western Medical Center, University of Maryland School of 
Medicine, Vanderbilt-Monroe Carell Jr. Children’s Hospital, 
UT Southwestern, UNC Chapel Hill, University of Chicago 
Children’s Hospital, LSU Health Science Center, Cooks 
Medical Center, and Willis-Knighton Physician Network) 
approved the study, and informed consent was obtained from 
all participants.
Study Population
The study population was recruited between August 
2011 and March 2014 from 12 participating sites. Serum 
and genomic DNA along with clinical data were obtained 
on all the subjects and entered into an electronic database 
(RedCap). All clinical information was obtained either at the 
time of  enrollment or by retrospective chart review. All cases 
had a diagnosis of  CD, based on standard diagnostic criteria, 
readily available serological results, and clearly documented 
disease behavior. Related individuals were removed from the 
study.11
Clinical Characteristics of CD Patients
Patients’ demographics, date of diagnoses, disease loca-
tion, disease behavior, surgical history, presence of extraint-
estinal manifestations (EIMs), smoking history, autoimmune 
history, family history, and history of biologic medication use 
were obtained either at the time of blood draw or via retro-
spective chart review. CD phenotype was classified in accord-
ance with the Montreal Classification for adults and Paris 
Classification for children.12, 13 For disease location, patients 
were classified into 1 of 4 mutually exclusive groups: L1 (ter-
minal ileal disease +/- limited cecal disease), L2 (colonic dis-
ease), L3 (ileocolonic disease), or L4 (isolated upper disease 
without evidence of ileal or colonic disease). The presence of 
upper gastrointestinal disease was categorized into 4 groups: 
0 (no disease), L4a (upper disease proximal to the Ligament 
of Treitz), L4b (upper disease distal to the Ligament of Treitz 
and proximal to the distal 1/3 ileum), and L4ab.13 Each patient’s 
disease behavior was categorized into 1 of 4 groups: B1 (non-
stricturing nonpenetrating disease), B2 (stricturing disease), B3 
(penetrating disease), and B2B3 (both stricturing and penetrat-
ing disease, either at the same moment in time or separately 
over a period of time).13 Complicated disease was defined as 
B2, B3, or B2B3. Perianal disease was positive if  the patient 
had any of the following: skin tag, anal fissure, perianal abscess, 
or perianal fistula. History of surgery was defined as any con-
firmed, documented surgical procedure necessary for the treat-
ment or management of CD except surgery related to existing 
perianal disease.
Serological Analysis
Blood samples were collected at the time of enrollment. 
Sera were measured for expression of ASCA IgG, ASCA IgA, 
anti-OmpC, anti-CBir1, and ANCA antibodies in a blinded 
fashion by an enzyme-linked immunosorbent assay (ELISA). 
The tests were run at Cedars-Sinai using previously described 
protocols and standards.14 Antibody levels were measured 
relative to the Cedars-Sinai Laboratory standard and were 
expressed in ELISA units (EU/mL).
All serological values were treated as continuous varia-
bles except when used for bivariable analysis, where they were 
analyzed as categorical variables. All cutoff  values were deter-
mined according to previous studies.14
Genotyping
 DNA samples were derived from whole blood. All DNA 
samples were genotyped by immnochip using the Illumina 
Immunochip, and the genotyped cells were made by using 
GenomeStudio version 2011. We have then extracted the data 
for NOD2/CARD15 single nucleotide polymorphsims (SNPs) 
rs2066844, rs2066846, and rs5743293.1 and Genotyping 
Module version 1.9.4. Samples were genotyped at Cedars-Sinai 
Medical Center. For analysis purposes, patients were catego-
rized by NOD2 genotype: NOD2-positive patients included 
those who carried at least 1 CD-associated NOD2 allele; 
NOD2-negative patients included those who carried only non-
risk alleles.
African Ancestry Estimation
Because AAs are well modeled as linear combinations of 
West African and European ancestries, we chose the WINPOP 
model in the LAMP package to estimate the locus-specific 
local ancestry. WINPOP takes allele frequencies from ances-
tral populations (YRI and CEU from HapMap) as input, and 
outputs the local ancestry estimate for each sample at each 
SNP as a proportion of YRI at values of 0, 0.5, or 1.15–17 The 
global YRI ancestry for each sample was estimated by using 
ADMIXTURE, which only requires sample genotypes and 
number of ancestral populations as input and outputs esti-
mated proportion from each ancestral population with a 
numeric value ranging from 0 to 1.18
Statistical Analysis
Statistical analyses were performed using SAS 9.3 (SAS 
Institute Inc., Cary, NC) and R 3.1.1 (R Foundation for 
Statistical Computing, Vienna, Austria). Statistical tests were 
2-sided, and a P value of less than 0.05 was considered statis-
tically significant. The Shapiro-Wilk Test was used to test for
normality on all continuous variables. Descriptive statistics are
presented as median (interquartile range) and percent (95%
confidence interval) for continuous and categorical outcomes,
respectively. Univariate analyses were performed to determine
associations between outcome, exposure, and predictor varia-
bles. Nonparametric Mann-Whitney tests were used for all con-
tinuous variables, and chi-square or Fisher exact tests were used 
for binomial variables. All independent terms were tested for lin-
earity with the log odds of the outcome using 5-knot restricted 
cubic splines (RCS) according to the method of Harrell.19 One-
knot linear splines were created based on review of the plot of 
the RCS and subject matter knowledge for those variables that 
did not meet this assumption. Multiple imputation by chained 
equations (MICE) was employed for multivariable analysis in 
order to account for data presumed to be missing at random.20 
Imputed data sets were only used for multivariable modeling.
A multivariable logistic regression model was used to 
evaluate the primary associations among serologic levels with 
the presence of complicated disease and disease requiring sur-
gery. All relevant demographic, phenotypic, genetic, and sero-
logical variables except history of surgery, history of biologic 
use, and outcome of interest were included in the initial model. 
Fast backward variable selection using Wald chi-square of indi-
vidual factors at the 0.05 significance level was performed until 
only statistically significant variables remained.21 Odds ratios 
and 95% confidence intervals were calculated using the 75th 
percentile to the 25th percentile for all continuous variables as 
a way to assess which variables have the largest impact over the 
same range. All initial and final models were tested for interac-
tion with percent African admixture.
RESULTS
Patient Characteristics
Data from 358 unrelated AA participants with CD were 
analyzed. The demographic and phenotypic characteristics of 
these participants are described in Table 1. The median age at 
diagnosis was 15 years (IQR, 12–22.5). Ileocolonic disease was 
observed in 53.6% of patients. Perianal disease was observed 
in 55.7%. Disease behavior was complicated in 41.6%. Biologic 
agents were used at some point in the disease course in 69.9% 
of patients. NOD2 positivity was observed in 5.9% of patients. 
More than 15% of data was missing for percent African admix-
ture. The median serological levels and respective IQR for all 
serological markers are displayed in Table 1. The distribution of 
percent African admixture in the cohort is illustrated in Fig. 1: 
Percent admixture rates range from 0.31 to 1.0, with a median 
of 0.83 (IQR, 0.8–0.9).
Patient Demographic and Phenotypic 
Characteristics According to Serological Status
Among the 358 AA patients with CD, 155 (43.3%) were 
(IgG and/or IgA) ASCA positive, 112 (31.3%) were anti-
OmpC positive, 177 (49.4%) were positive for anti-CBir1, 
and 61 (17.0%) were positive for ANCA. The demographic 
and phenotypic characteristics of participants according to 
serological status are displayed in Table 2. On univariate ana-
lysis, the following characteristics were associated with ASCA 
positivity: personal history of immune-mediated (P  =  0.02), 
EIM (P  =  0.02), complicated disease (P  <  0.0001), ileal dis-
ease (P < 0.0001), and disease requiring surgery (P = 0.002). 
Anti-OmpC positivity was significantly associated with age 
at enrollment (P  =  0.005), complicated disease (P  =  0.02), 
and disease requiring surgery (P  <  0.0001). Anti-CBir1 posi-
tivity was associated with age at enrollment (P = 0.001), age at 
diagnosis (P = 0.008), percent African admixture (P = 0.004), 
current smoke exposure (P = 0.004), and isolated ileal disease 
(P = 0.03). A negative ANCA was significantly associated with 
EIM (P = 0.01), complicated disease (P = 0.003), and ileal dis-
ease (P = 0.01).
Patient Characteristics and Serological Levels 
Associated With Complicated Disease
One-knot linear splines were set at 15 EU/mL, 20 EU/
mL, and 20 EU/mL for the variables ASCA IgG, anti-OmpC, 
and anti-CBir1, respectively (Supplemental Digital Content, 
Fig. S1). The final multivariable model (Table  3), after fast 
backwards selection of  individual factors at the 0.05 signifi-
cance level, showed that OmpC (OR, 2.23; 95% CI, 1.41–3.53), 
IgG ASCA (OR, 2.67; 95% CI, 1.67–4.28), and ileal disease 
(OR, 2.94; 95% CI, 5.26–8.77) were independently associated 
with complicated disease. There was no interaction between 
NOD2 positivity and any of  the serological markers in the 
final model. Additionally, the interaction between percent 
African admixture and all covariates included in the initial 
and final model was assessed and found to be insignificant.
TABLE 1. Demographic and Phenotypic Characteristics 
of Cohort
Variable Median (IQR) or No. (%)
African admixturea 0.83 (0.8–0.9)
Age (IGR), y 20 (15–36)
Age at diagnosis (IQR), y 15 (12–22.5)
Age category at diagnosis, y
A1: younger than 16 180 (51.1%)
A2: between 17 and 40 147 (41.7%)
A3: older than 40 25 (7.1%)
Male sex, No. (%) 181 (50.6%)
Family history of IBD, No. (%) 27 (8.2%)
History of autoimmune disorder, No. (%) 96 (27.7%)
Extraintestinal manifestations, No. (%) 95 (27.7%)
Smoking (ever), No. (%) 135 (42.4%)
Disease location, No. (%)
L1: ileal 42 (13.2%)
L2: colonic 106 (33.2%)
L3: ileocolonic 171 (53.6%)
L4: isolated upper 0 (0.0%)
Upper disease modifier, No. (%)
No disease 198 (63.6%)
 L4Ab 73 (23.5%)
 L4B 20 (6.4%)
 L4AB 20 (6.4%)
Disease behavior, No. (%)
B1: inflammatory 209 (58.4%)
B2: stricturing 6 (18.2%)
B3: penetrating 37 (10.3%)
B2B3: stricturing and penetrating 47 (13.1%)
Complicated disease, No. (%) 149 (41.6%)
Perianal disease,a No. (%) 156 (55.7%)
Surgical history, No. (%) 128 (40.1%)
Biologic use (ever), No. (%) 229 (69.9%)
NOD2 positivity, No. (%) 20 (5.9%)
Serological responsec (level)
ASCA IgA 7.1 (2.3–26.7)
ASCA IgG 21.1 (5.9–53.5)
 Anti-OmpC 15.7 (9.9–27.7)
 Anti-CBir1 24.2 (14.4–46.1)
 pANCA 16.4 (10.3–23.4)
Serological response, No. (%)
ASCA IgA 125 (34.9%)
ASCA IgG 117 (32.7%)
 Anti-OmpC 112 (31.3%)
 Anti-CBir1 177 (49.4%)
 pANCA 61 (17.0%)
aMissing Greater than 15% of the data.
bL4A: disease proximal to the ligament of treitz; L4B: disease distall to the ligament 
of treitz but proximal to the distal 1/3 of the ileum.
cResults are classified a s n egative o r p ositive a ccording t o t he m anufacturer’s 
determined cutoffs. A negative response was defined as: ASCA IgA < 20 EU/mL; 
ASCA IgG  <  40 EU/mL; anti-OmpC  <  23 EU/mL; anti-CBir1  <  25 EU/mL; 
pANCA < 17.46 EU/Ml.
anti-Cbir1 = flagellin-like bacterial antigen; Panca = perinuclear antinuclear cytoplas-
mic antibody.
FIGURE 1. Percent African admixture. The distribution of African 
admixture among all study participants. The median percent admixture 
was 0.83 percent, indicating that the genetic make-up of the majority 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Patient Characteristics and Serological Levels 
Associated With Surgery
One-knot linear splines were set at 25  years, 40 EU/
mL, 20 EU/mL, and 20 EU/mL for the variables age at diag-
nosis, IgA ASCA, IgG ASCA, and anti-OmpC, respectively 
(Supplemental Digital Content, Fig. S2). The final multivaria-
ble model (Table 4), after fast backwards selection of individual 
factors at the 0.05 significance level, showed that disease requir-
ing surgery was independently associated with NOD2 positivity 
(OR, 2.9; 95% CI, 1.01–8.33), IgG ASCA (OR, 2.51, 95% CI, 
1.49–4.22), and anti-OmpC (OR, 3.57; 95% CI, 2.12–6.00). 
There was no interaction between NOD2 positivity and any of 
the serological markers in the final model. Additionally, inter-
action between percent African admixture and all covariates 
included in the initial models and the final remaining model 
was assessed and found to be insignificant.
DISCUSSION
Our study was designed to describe the phenotypic be-
havior of CD in AAs and to explore the relationship between 
antimicrobial serology and disease outcomes, while controlling 
for genetic ancestry. Our series comprises the largest cohort of 
AAs with CD and is the first study to evaluate anti-OmpC, anti-
CBir1, and ANCA and their association with phenotype and 
disease behavior.
We found that the majority of AAs with CD had 
in-flammatory, noncomplicated disease type (58.4%), mostly 
the colon (86.8%). Fifty-three percent of patients with colonic 
dis-ease also had disease affect the small bowel, and 55.7% of 
our patients had perianal disease at the time of enrollment. 
Our 
observations regarding primary disease location and disease be-
havior concur with the findings of both Mahid et al. and Hou 
et al., who published systematic reviews on the epidemiology 
and phenotypic presentation of IBD in AAs.7, 8 These findings 
are also consistent with those found in European ancestry pop-
ulations, which is contrary to earlier literature reporting that 
AAs have a more severe course with different disease distribu-
tion.22, 23
However, we found a notably higher prevalence of peri-
anal disease than previously reported. Mahid et al. reported the 
prevalence of perianal disease to be 26%, Hou et al. reported 
a prevalence of 25%, and Dassopoulos et al. reported a preva-
lence of 34%. In other reports, the prevalence of perianal dis-
ease ranged from 0% to 60%.24–31 The wide range appears to 
be a function of (i) the sample size, (ii) the disease severity 
of the patient population, and (iii) the definition of perianal 
disease. The perianal disease modifier, as described in the 
Montreal Classification, includes skin tags, anal fissures, peri-
anal abscesses, or perianal fistulas, but many studies either did 
not clarify how perianal disease was defined or included only 
perianal abscesses and fistulas in their definition.12, 13
While numerous studies have reported the presence and 
magnitude of serological antibodies with complicated disease, 
ileal involvement, and earlier-onset disease in NE populations, 
less is known about these associations in AAs. Dassopoulos et al. 
conducted the first study to assess ASCA levels in AAs with CD. 
They reported that, similar to NEs, ASCA was independently 
associated with complicated behavior and surgery in AAs with 
CD.9 Our study expands upon this study by exploring the associ-
ation between ASCA, anti-OmpC, anti-CBir1, and ANCA with
complicated disease and disease requiring surgery. We not only
TABLE 3. Adjusted Odds Ratio for Complicated Crohn’s Disease
Odds Ratioa 95% Confidence Interval
Anti-OmpCb Comparing 27.7 EU/mL with 17.7 EU/mL 2.23 1.41–3.53
IgG ASCAb Comparing 53.5 EU/mL with 5.9 EU/mL 2.67 1.67–4.28
Ileal disease Positive to negative 2.94 5.26–8.77
aORs were calculated by comparing the 75th percentile with the 25th percentile.
bOne-knot linear splines were created based on review of restricted cubic spline and subject matter knowledge.
TABLE 4. Adjusted Odds Ratio for Disease Requiring Surgery
Odds Ratioa 95% Confidence Interval
NOD2 positivity Positive to negative 2.9 1.01–8.33
IgG ASCAb Comparing 53.3 EU/mL with 5.9 EU/mL 2.51 1.49–4.22
Anti-OmpCb Comparing 27.7 EU/mL with 9.9 EU/mL 3.57 2.12–6.00
aORs were calculated by comparing the 75th percentile with the 25th percentile.
bOne-knot linear splines were created based on review of restricted cubic spline and subject matter knowledge.
confirmed the association between IgG ASCA with complicated 
disease and surgeries but also identified an association between 
anti-OmpC with complicated disease and disease requiring sur-
gery in AAs. We also found that IgG ASCA remained statis-
tically significant after controlling for ileal disease, NOD2 
positivity, and percent African Admixture. In contrast to prior 
reports, in which ASCAs were known to be associated with 
white populations, ileal involvement, and NOD2 status, the as-
sociation between ASCA and complicated disease and disease 
requiring surgery is not the result of European admixture.9, 32 
Our findings do concur with prior literature regarding the as-
sociation between anti-OmpC with complicated disease and the 
need for surgery in NE populations.5, 33, 34
Dubinsky et al. were the first to tabulate antibody sum 
scores in NEs and found that the frequency of internal pene-
trating disease, stricturing disease, and disease requiring surgery 
increased as the number of immune responses increased.5 In a 
subanalysis, we calculated antibody sum scores according to 
the method described by Dubinsky et al. and observed similar 
results (Supplemental Digital Content, Fig. S3).5 We saw an in-
crease in complicated behavior types (B2, B3, and B2B3) with 
a higher sum score, and, conversely, inflammatory disease (B1) 
was least present in the highest-sum group.
These findings suggest that the phenotypes of CD in 
Caucasians and AAs are not as dissimilar as initially believed.22,  23 
We hypothesized that the genetic differences between AAs and 
NEs would result in statistically significant, clinically mean-
ingful differences between antimicrobial antibodies and their re-
lationship with disease phenotype in CD. We also hypothesized 
that there would be an interaction between African admixture 
and serological levels, which was also not observed. Contrary 
to our initial hypotheses, we found that antimicrobial antibod-
ies and their association with disease phenotype and behavior 
can be interpreted similarly between AAs and NEs. We postu-
late that these similarities are more of a function of similari-
ties among the intestinal microbiota than differences in genetic 
make-up, emphasizing the role of the environment and the limi-
tation of genetics to diagnose IBD or predict disease behavior.1 
These findings are further corroborated by twin concordance 
studies that have demonstrated that only a small percentage of 
the risk of developing inflammatory bowel disease is related to 
genetics.35
Limitations of our study include the substantial missing 
data from our participant population and the predominance 
of participants diagnosed younger than age 16  years. While 
there was no missing data related to serological levels, we were 
missing more than 15% of data in variables measuring the pres-
ence of perianal disease and percent African admixture. Eleven 
additional confounding variables were missing values for any-
where between 1.4% and 14.0% of the participants. As a result, 
our sample size decreased by more than 50% when we per-
formed the multivariable analysis using our original model. We 
addressed this limitation by performing multiple imputations 
by chained equations, a principled method of dealing with miss-
ing data.20 We were also limited by the absence of demographic 
or phenotypic information on those patients who chose not to 
participate. Additionally, our study population was based on 
a population with a pediatric majority. The majority of our 
patients were diagnosed younger than age 16  years, which is 
not reflective of the general population and likely suggests a 
population with more severe disease.
In contrast to the hypothesis that the diagnostic value of 
antimicrobial and autoimmune antibodies would vary among 
different ethnic and geographic populations due to differences 
in environmental and genetic influences, we found that with re-
spect to ASCA and anti-OmpC, they behave similarly in AA 
and NE populations recruited from similar geographic areas.4 
Our study also provides reassurance that the utility of sero-
logical markers for prognosis of CD applies equally to AA 
populations.
ACKNOWLEDGMENTS
Author contributions: Madeline Bertha helped concep-
tualize the paper, contributed to data acquisition, performed 
statistical analysis, wrote the manuscript, and reviewed and 
approved the final manuscript. Arthi Vasantharoopan contrib-
uted to statistical analysis, contributed to the manuscript, and 
reviewed and approved the final manuscript. Archana Kumar 
helped conceptualize the paper, contributed to data acqui-
sition, contributed to statistical analysis, contributed to the 
manuscript, and reviewed and approved the final manuscript. 
Beau Bruce helped conceptualize the paper, performed statis-
tical analysis, contributed to the manuscript, and reviewed and 
approved the final manuscript. Tatyana Hofmekler contributed 
to the manuscript and reviewed and approved the final manu-
script. Jarod Prince contributed to data acquisition, contrib-
uted to the manuscript, and reviewed and approved the final 
manuscript. Cary Sauer helped contribute to the manuscript 
and reviewed and approved the final manuscript. Dermot 
McGovern conceptualized the manuscript, performed the 
assays, helped contributed to the manuscript, and reviewed and 
approved the final manuscript. Subra Kugathasan is the prin-
ciple investigator of this project and responsible for the overall 
conduct, results, and conclusions of the paper. He conceptual-
ized the paper, contributed to the manuscript, and reviewed and 
approved the final manuscript. All other authors contributed to 
the acquisition of data.
REFERENCES
1. Gerich ME, McGovern DP. Towards personalized care in ibd. Nat Rev
Gastroenterol Hepatol. 2014;11:287–299.
2. Mow WS, Landers CJ, Steinhart AH, et al. High-level serum antibodies to bac-
terial antigens are associated with antibiotic-induced clinical remission in Crohn’s 
disease: a pilot study. Dig Dis Sci. 2004;49:1280–1286.
3. Papp M, Altorjay I, Dotan N, et  al; Hungarian IBD Study Group. New sero-
logical markers for inflammatory bowel disease are associated with earlier age at 
onset, complicated disease behavior, risk for surgery, and nod2/card15 genotype
in a hungarian ibd cohort. Am j Gastroenterol. 2008;103:665–681.
4. Prideaux L, De Cruz P, Ng SC, et  al. Serological antibodies in inflammatory
bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18:1340–1355.
5. Dubinsky MC, Kugathasan S, Mei L, et  al; Western Regional Pediatric IBD
Research Alliance; Pediatric IBD Collaborative Research Group; Wisconsin
Pediatric IBD Alliance. Increased immune reactivity predicts aggressive compli-
cating Crohn’s disease in children. Clin Gastroenterol Hepatol. 2008;6:1105–1111.
6. Straus WL, Eisen GM, Sandler RS, et al. Crohn’s disease: does race matter? The 
Mid-Atlantic Crohn’s Disease Study Group. Am j Gastroenterol. 2000;95:479–483.
7. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflam-
matory bowel disease in Asians, Hispanics, and African Americans: a systematic 
review. Am j Gastroenterol. 2009;104:2100–2109.
8. Mahid SS, Mulhall AM, Gholson RD, et  al. Inflammatory bowel disease and
African Americans: a systematic review. Inflamm Bowel Dis. 2008;14:960–967.
9. Dassopoulos T, Nguyen GC, Talor MV, et al; NIDDK IBD Genetics Consortium. 
nod2 mutations and anti-saccharomyces cerevisiae antibodies are risk factors for 
Crohn’s disease in African Americans. Am j Gastroenterol. 2010;105:378–386.
10. Tishkoff SA, Reed FA, Friedlaender FR, et al. The genetic structure and history 
of Africans and African Americans. Science. 2009;324:1035–1044.
11. Bernstein CN, Fried M, Krabshuis JH, et  al. World Gastroenterology
Organization practice guidelines for the diagnosis and management of ibd in
2010. Inflamm Bowel Dis. 2010;16:112–124.
12. Satsangi J, Silverberg MS, Vermeire S, et al. The montreal classification of inflamma-
tory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
13. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal 
classification for inflammatory bowel disease: the Paris classification. Inflamm 
Bowel Dis. 2011;17:1314–1321.
14. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by
Crohn’s disease-associated immune responses to auto- and microbial antigens.
Gastroenterology. 2002;123:689–699.
15. Price AL, Helgason A, Palsson S, et al. The impact of divergence time on the nature
of population structure: an example from Iceland. Plos Genet. 2009;5:e1000505.
16. Pasaniuc B, Sankararaman S, Kimmel G, et  al. Inference of locus-specific an-
cestry in closely related populations. Bioinformatics. 2009;25:i213–i221.
17. Seldin MF, Pasaniuc B, Price AL. New approaches to disease mapping in admixed 
populations. Nat Rev Genet. 2011;12:523–528.
18. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry 
in unrelated individuals. Genome Res. 2009;19:1655–1664.
19. Harrell F. Regression Modeling Strategies: With Applications to Linear Models,
Logistic Regression, and Survival Analysis. New York: Springer-Verlag, Inc.; 2001.
20. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equa-
tions: what is it and how does it work? Int j Methods Psychiatr Res. 2011;20:40–49.
21. Lawless JF, Singhal K. Efficient screening of non-normal regression models.
Biometrics. 1978;34:318–327.
22. Agrez MV, Valente RM, Pierce W, et al. Surgical history of Crohn’s disease in a
well-defined population. Mayo Clin Proc. 1982;57:747–752.
23. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory 
bowel disease within the United States. Gastroenterology. 1991;100:143–149.
24. Basu D, Lopez I, Kulkarni A, et al. Impact of race and ethnicity on inflammatory 
bowel disease. Am j Gastroenterol. 2005;100:2254–2261.
25. Cross RK, Jung C, Wasan S, et al. Racial differences in disease phenotypes in
patients with Crohn’s disease. Inflamm Bowel Dis. 2006;12:192–198.
26. Deveaux PG, Kimberling J, Galandiuk S. Crohn’s disease: presentation and se-
verity compared between black patients and white patients. Dis Colon Rectum. 
2005;48:1404–1409.
27. Goldman CD, Kodner IJ, Fry RD, et al. Clinical and operative experience with
non-Caucasian patients with Crohn’s disease. Dis Colon Rectum. 1986;29:317–321.
28. Mahid SS, Minor KS, Stromberg AJ, et al. Active and passive smoking in child-
hood is related to the development of inflammatory bowel disease. Inflamm Bowel 
Dis. 2007;13:431–438.
29. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease character-
istics among African Americans, Hispanics, and non-Hispanic whites: characteriza-
tion of a large North American cohort. Am j Gastroenterol. 2006;101:1012–1023.
30. Ogunbi SO, Ransom JA, Sullivan K, et  al. Inflammatory bowel disease in
African-American children living in Georgia. j Pediatr. 1998;133:103–107.
31. Simsek H, Schuman BM. Inflammatory bowel disease in 64 black patients: ana-
lysis of course, complications, and surgery. j Clin Gastroenterol. 1989;11:294–298.
32. Adeyanju O, Okou DT, Huang C, et al. Common nod2 risk variants in African
Americans with Crohn’s disease are due exclusively to recent Caucasian admix-
ture. Inflamm Bowel Dis. 2012;18:2357–2359.
33. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflam-
matory bowel disease are associated with complicated disease behaviour. Gut. 
2007;56:1394–1403.
34. Mow WS, Vasiliauskas EA, Lin YC, et  al. Association of antibody responses
to microbial antigens and complications of small bowel Crohn’s disease.
Gastroenterology. 2004;126:414–424.
35. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish
twin cohort: a long-term follow-up of concordance and clinical characteristics.
Gastroenterology. 2003;124:1767–1773.
